Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction
Open Access
- 1 February 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 31 (1) , 96-104
- https://doi.org/10.1093/ije/31.1.96
Abstract
Background There has been extensive discussion of the apparent conflict between meta-analyses and a mega-trial investigating the benefits of intravenous magnesium following myocardial infarction, in which the early trial results have been said to be ‘too good to be true’. Methods We apply Bayesian methods of meta-analysis to the trials available before and after the publication of the ISIS-4 results. We show how scepticism can be formally incorporated into an analysis as a Bayesian prior distribution, and how Bayesian meta-analysis models allow appropriate exploration of hypotheses that the treatment effect depends on the size of the trial or the risk in the control group. Results Adoption of a sceptical prior would have led early enthusiasm for magnesium to be suitably tempered, but only if combined with a random effects meta-analysis, rather than the fixed effect analysis that was actually conducted. Conclusions We argue that neither a fixed effect nor a random effects analysis is appropriate when the mega-trial is included. The Bayesian framework provides many possibilities for flexible exploration of clinical hypotheses, but there can be considerable sensitivity to apparently innocuous assumptions.Keywords
This publication has 51 references indexed in Scilit:
- Rationale and design of the Magnesium in Coronaries (MAGIC) study: A clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarctionAmerican Heart Journal, 2000
- META-ANALYSIS IN THE DESIGN AND MONITORING OF CLINICAL TRIALSStatistics in Medicine, 1996
- Review of clinical evidence – is there a role for supplemental magnesium in acute myocardial infarction in high-risk populations (patients ineligible for thrombolysis and the elderly)?Coronary Artery Disease, 1996
- Results of randomized clinical trials of magnesium - can a consensus be reached?Coronary Artery Disease, 1996
- Magnesium, myocardial infarction, meta-analysis and megatrialsDrug and Therapeutics Bulletin, 1995
- Magnesium and myocardial infarctionThe Lancet, 1994
- Role of Magnesium in Reducing Mortality in Acute Myocardial InfarctionDrugs, 1993
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985
- ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASEAnnals of Human Genetics, 1955